rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Absci Corporation

ABSI · Nasdaq

Health CareLife-science toolsLeadingSynthetic Biology / TechBio

ABSI stood above a rising 150-day average in 37 of the last 52 weekly readings, including each of the last 27 weeks. It is 23.8% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+1 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
27 in a row
Industry in uptrend
52% +1 in 4 wk
Insider buys, 12 months
$1.7M
Insider sales, 12 months
$265K
Officials’ trades on record
0
Institutions holding
188 (+33)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 37 of 52 weeks.

21 Apr – 20 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$239K$0$432KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months2
Buyers · sellers4 · 2
WhoDidSharesTraded
Mary T. SzelaDirectorbought12,900at $11.5430 Jun 2026filed 6 Jul 2026
Menelas N. PangalosDirectorbought37,453at $5.3613 May 2026filed 13 May 2026
Andreas BuschChief Innovation Officerbought100,000at $2.2912 Mar 2026filed 16 Mar 2026
Menelas N. PangalosDirectorbought75,095at $2.7427 Feb 2026filed 3 Mar 2026
Zachariah JonassonCFO / CBOsold17,496at $2.992 Feb 2026filed 4 Feb 2026
Sean McClainChief Executive Officersold26,761at $2.992 Feb 2026filed 4 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders188+33 on the quarter
New · exited53 · 19
Reported value$1.7B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202625,410,048$294.5M+2,859,051+12.7%
ARK Investment Management LLCreduced · filed 14 Aug 202612,925,271$149.8M-800,898−5.8%
BlackRock, Inc.added · filed 7 Aug 202612,175,302$141.1M+920,108+8.2%
STATE STREET CORPadded · filed 7 Aug 20268,097,308$93.8M+772,450+10.5%
AMERIPRISE FINANCIAL INCadded · filed 14 Aug 20266,991,763$81.0M+3,811,622+119.9%
Redmile Group, LLCreduced · filed 14 Aug 20266,739,675$78.1M-1,513,641−18.3%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 20266,122,677$71.0M+6,122,677
ADVANCED MICRO DEVICES INCunchanged · filed 14 Aug 20265,714,285$66.2M00.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.new · filed 14 Aug 20265,704,820$66.1M+5,704,820
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20265,493,486$63.7M+2,594,720+89.5%
31 Mar 2023 – 30 Jun 2026
62122183Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Sean McClain Company insiderChief Executive Officer · last 12 Oct 20262 · 1
Todd Bedrick Company insiderSVP, CAO · last 12 Oct 20263 · 0
Zachariah Jonasson Company insiderCFO / CBO · last 12 Oct 20261 · 2
Ransi Mudalinayake Somaratne Company insiderCMO, Head of R&D · last 3 Aug 20260 · 0
Mary T. Szela Company insiderDirector · last 30 Jun 20261 · 0
Daniel A. Rabinovitsj Company insiderDirector · last 4 Jun 20260 · 0
Frans Van Houten Company insiderDirector · last 4 Jun 20261 · 0
Joseph Sirosh Company insiderDirector · last 4 Jun 20260 · 0
Karen K. McGinnis Company insiderDirector · last 4 Jun 20261 · 0
Menelas N. Pangalos Company insiderDirector · last 4 Jun 20263 · 0
Andreas Busch Company insiderChief Innovation Officer · last 12 Mar 20262 · 0
Shelby J. Walker Company insiderChief Legal Officer · last 3 Mar 20260 · 0

Same industry

OABI OmniAbLeading+75%
TXG 10x GenomicsLeading+61%
AVTR AvantorLeading+48%
ILMN IlluminaLeading+46%
RVTY RevvityLeading+39%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-62.2%
Share count trendFY 2025 · to 6 Mar 202611.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$20.0M
Free cash flowFY 2025 · to 31 Dec 2025−$94.0M

Analyst forecasts

No analyst forecasts yet.